Cargando…

(Z)-Endoxifen and Early Recurrence of Breast Cancer: An Explorative Analysis in a Prospective Brazilian Study

Adherence to treatment and use of co-medication, but also molecular factors such as CYP2D6 genotype, affect tamoxifen metabolism, with consequences for early breast cancer prognosis. In a prospective study of 149 tamoxifen-treated early-stage breast cancer patients from Brazil followed up for 5 year...

Descripción completa

Detalles Bibliográficos
Autores principales:	Almeida, Thais, Schroth, Werner, Nardin, Jeanine, Mürdter, Thomas E., Winter, Stefan, Picolotto, Solane, Hoppe, Reiner, Kogin, Jenifer, Gaio, Elisa, Dasenbrock, Angela, Skrsypcsak, Raquel Cristina, de Noronha, Lucia, Schwab, Matthias, Brauch, Hiltrud, Casali-da-Rocha, José Claudio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9030524/ https://www.ncbi.nlm.nih.gov/pubmed/35455627 http://dx.doi.org/10.3390/jpm12040511

Ejemplares similares

The Influences of Adherence to Tamoxifen and CYP2D6 Pharmacogenetics on Plasma Concentrations of the Active Metabolite (Z)‐Endoxifen in Breast Cancer
por: Nardin, Jeanine Marie, et al.
Publicado: (2019)

Improved Prediction of Endoxifen Metabolism by CYP2D6 Genotype in Breast Cancer Patients Treated with Tamoxifen
por: Schroth, Werner, et al.
Publicado: (2017)

Concomitant use of tamoxifen and endoxifen in postmenopausal early breast cancer: prediction of plasma levels by physiologically-based pharmacokinetic modeling
por: Dickschen, Kristin, et al.
Publicado: (2014)

The formation of estrogen-like tamoxifen metabolites and their influence on enzyme activity and gene expression of ADME genes
por: Johänning, Janina, et al.
Publicado: (2017)

Simulation-Based Assessment of the Impact of Non-Adherence on Endoxifen Target Attainment in Different Tamoxifen Dosing Strategies
por: Mueller-Schoell, Anna, et al.
Publicado: (2021)

Exploiting the complexity of the genome and transcriptome using pharmacogenomics towards personalized medicine
por: Hoppe, Reiner, et al.
Publicado: (2011)

Profiles of miRNAs matched to biology in aromatase inhibitor resistant breast cancer
por: Hoppe, Reiner, et al.
Publicado: (2016)

Cancer-Associated Intermediate Conductance Ca(2+)-Activated K(+) Channel K(Ca)3.1
por: Mohr, Corinna J., et al.
Publicado: (2019)

Endoxifen, a New Treatment Option for Mania: A Double‐Blind, Active‐Controlled Trial Demonstrates the Antimanic Efficacy of Endoxifen
por: Ahmad, A, et al.
Publicado: (2016)

Patient safety and the value of pharmaceutical intervention in a cancer hospital
por: Aguiar, Karina da Silva, et al.
Publicado: (2018)

CYP2D6 genotype- and endoxifen-guided tamoxifen dose escalation increases endoxifen serum concentrations without increasing side effects
por: Dezentjé, V. O., et al.
Publicado: (2015)

Association of CYP2D6 metabolizer status with mammographic density change in response to tamoxifen treatment
por: Li, Jingmei, et al.
Publicado: (2013)

Augmentation of Endoxifen Exposure in Tamoxifen-Treated Women Following SSRI Switch
por: Binkhorst, Lisette, et al.
Publicado: (2015)

Orally administered endoxifen inhibits tumor growth in melanoma-bearing mice
por: Chen, Paul, et al.
Publicado: (2018)

Exposure–response analysis of endoxifen serum concentrations in early-breast cancer
por: Sanchez-Spitman, Anabel Beatriz, et al.
Publicado: (2020)

Endoxifen and fulvestrant regulate estrogen-receptor α and related DEADbox proteins
por: Asberger, Jasmin, et al.
Publicado: (2020)

Topical Endoxifen for Mammographic Density Reduction—A Randomized Controlled Trial
por: Bäcklund, Magnus, et al.
Publicado: (2022)

Phase 1 study of Z-endoxifen in patients with advanced gynecologic, desmoid, and hormone receptor-positive solid tumors
por: Takebe, Naoko, et al.
Publicado: (2021)

The Effects of a Novel Hormonal Breast Cancer Therapy, Endoxifen, on the Mouse Skeleton
por: Gingery, Anne, et al.
Publicado: (2014)

Real-World Long-Term Experience on Endoxifen in Bipolar Disorder with Psychotic Symptoms
por: Thanvi, Vikas
Publicado: (2022)

Antitumor activity of Z-endoxifen in aromatase inhibitor-sensitive and aromatase inhibitor-resistant estrogen receptor-positive breast cancer
por: Jayaraman, Swaathi, et al.
Publicado: (2020)

SK4 channels modulate Ca(2+) signalling and cell cycle progression in murine breast cancer
por: Steudel, Friederike A., et al.
Publicado: (2017)

Estrogen receptor-beta sensitizes breast cancer cells to the anti-estrogenic actions of endoxifen
por: Wu, Xianglin, et al.
Publicado: (2011)

Endoxifen’s Molecular Mechanisms of Action Are Concentration Dependent and Different than That of Other Anti-Estrogens
por: Hawse, John R., et al.
Publicado: (2013)

Transporting Antitumor Drug Tamoxifen and Its Metabolites, 4-Hydroxytamoxifen and Endoxifen by Chitosan Nanoparticles
por: Agudelo, Daniel, et al.
Publicado: (2013)

Cost-effectiveness of monitoring endoxifen levels in breast cancer patients adjuvantly treated with tamoxifen
por: van Nuland, M., et al.
Publicado: (2018)

Targeting Estrogen Receptor-Positive Breast Microtumors with Endoxifen-Conjugated, Hypoxia-Sensitive Polymersomes
por: Mamnoon, Babak, et al.
Publicado: (2021)

Influence of probenecid on endoxifen systemic exposure in breast cancer patients on adjuvant tamoxifen treatment
por: Buck, Stefan A. J., et al.
Publicado: (2022)

Curcumin for the Prevention of Epithelial-Mesenchymal Transition in Endoxifen-Treated MCF-7 Breast Cancer Cells
por: Paramita, P, et al.
Publicado: (2018)

Tamoxifen metabolism predicts drug concentrations and outcome in premenopausal patients with early breast cancer
por: Saladores, P, et al.
Publicado: (2015)

Generation of brain tumours in mice by Cre-mediated recombination of neural progenitors in situ with the tamoxifen metabolite endoxifen
por: Benedykcinska, Anna, et al.
Publicado: (2016)

Endoxifen, 4-Hydroxytamoxifen and an Estrogenic Derivative Modulate Estrogen Receptor Complex Mediated Apoptosis in Breast Cancer
por: Maximov, Philipp Y., et al.
Publicado: (2018)

Influence of green tea consumption on endoxifen steady-state concentration in breast cancer patients treated with tamoxifen
por: Braal, C. Louwrens, et al.
Publicado: (2020)

Generating a Precision Endoxifen Prediction Algorithm to Advance Personalized Tamoxifen Treatment in Patients with Breast Cancer
por: Helland, Thomas, et al.
Publicado: (2021)

Therapeutic Drug Monitoring of Endoxifen for Tamoxifen Precision Dosing: Feasible in Patients with Hormone-Sensitive Breast Cancer
por: Braal, C. Louwrens, et al.
Publicado: (2021)

The impact of endoxifen-guided tamoxifen dose reductions on endocrine side-effects in patients with primary breast cancer
por: Buijs, S.M., et al.
Publicado: (2023)

Addressing Adherence Using Genotype-Specific PBPK Modeling—Impact of Drug Holidays on Tamoxifen and Endoxifen Plasma Levels
por: Dickschen, Kristin J. R., et al.
Publicado: (2017)

Simplified phenotyping of CYP2D6 for tamoxifen treatment using the N-desmethyl-tamoxifen/ endoxifen ratio
por: Lee, Clara Inkyung, et al.
Publicado: (2020)

Downregulation of 15-hydroxyprostaglandin dehydrogenase during acquired tamoxifen resistance and association with poor prognosis in ERα-positive breast cancer
por: Volpato, Milene, et al.
Publicado: (2020)

Design, Synthesis and Biochemical Evaluation of Novel Selective Estrogen Receptor Ligand Conjugates Incorporating an Endoxifen-Combretastatin Hybrid Scaffold
por: Keely, Niall O., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_6ucscgj3jvv2q1h8tfsbv43m7b